目的目前临床治疗中利用调强放射治疗(IMRT)联合化疗治疗非小细胞癌(NSCLC)的研究较少。文中旨在分析化疗联合IMRT治疗局部进展期NSCLC患者的疗效及对生存质量的影响。方法选择2012年1月至2014年12月苏州大学附属第一医院放疗科收治的16...目的目前临床治疗中利用调强放射治疗(IMRT)联合化疗治疗非小细胞癌(NSCLC)的研究较少。文中旨在分析化疗联合IMRT治疗局部进展期NSCLC患者的疗效及对生存质量的影响。方法选择2012年1月至2014年12月苏州大学附属第一医院放疗科收治的160例局部进展期NSCLC患者,根据治疗方式不同分为IMRT组(紫杉醇或吉西他滨联合顺铂化疗,调强放射治疗)和对照组(仅紫杉醇或吉西他滨联合顺铂化疗),每组80例。比较2组患者治疗效果及对患者生存质量的影响。结果 IMRT组治疗有效率高于对照组(78.75%vs 47.50%,P<0.05)。IMRT组患者1年、2年、3年生存率(70.00%、52.50%、36.25%)明显高于对照组(52.50%、36.25%、21.25%),差异有统计学意义(P<0.05)。IMRT组患者中位疾病进展时间、中位生存期明显大于对照组[8.9 vs 6.3个月,14.2 vs 11.1个月],差异均有统计学意义(P<0.05)。IMRT组不良反应发生率与对照组比较差异无统计学意义(P>0.05)。结论局部进展期NSCLC者采用化疗联合IMRT能显著提高治疗效果,不良反应较少,安全性高,明显延长患者生存期,值得临床推广使用。展开更多
Objective： To study the clinical efficacy and methods of permanent implantation of radioactive I-125 seed in surgery for local advanced non small lung cancer （LANSCLC）. Methods： From Apr. 2004 to Apr. 2006, the I-...Objective： To study the clinical efficacy and methods of permanent implantation of radioactive I-125 seed in surgery for local advanced non small lung cancer （LANSCLC）. Methods： From Apr. 2004 to Apr. 2006, the I-125 seeds were implanted into 30 patients with LANSCLC in surgery. The numbers of seeds were 10-40. The chemotherapy was performed in 10 to 14 days after operation. Results： There was no operative death, and the distribution of seeds and complications were reviewed by CT and X-ray after treatment. The distribution of seeds was satisfactory in all patients. The complete response rate （CR） was 56.6% and the part response （PR） was 26.6%. The overall response rate was 83.3% after 4-24 months of surgery. There was no one occurred radiation pneumonia. Prospective efficacy await further follow-up. Conclusion： Permanent implantation of 1-125 seed in surgery for LANSCLC, is a safe and effective method with mild complications.展开更多
During a 12-year period, 44 patients were surgically treated for stage- Ⅲ peripheral squamous cell car-cinoma of the right upper lobe. The mean time from the discovery of the shadow in the right upper lobe tothe conf...During a 12-year period, 44 patients were surgically treated for stage- Ⅲ peripheral squamous cell car-cinoma of the right upper lobe. The mean time from the discovery of the shadow in the right upper lobe tothe confirmation of the diagnosis was 2 months. All patients underwent the resection of the right upperlobe with the dissection of the right mediastinal lymph nodes, among them, 4 patients had sleeve lobectomy of the right upper lobe. P-TNM staging: 23 cases were in stage- Ⅲ a, 21 cases in stage- Ⅲ b. The fre-quency of the postoperative complications was 20- 4 % (9/44 cases). The 1-year survival rate of all patientswas 61 % (27/44 cases). None of stage - Ⅲ b patients lived longer than 3 years. The postoperative 3-and 5-year survival rates of stage- Ⅲ a cases were 65. 2 % (15/23cases) and 21. 7 % (5/23 cases) respectively. Inthis article, the patients clinical features, the causes of delayed-diagnosis, the operative and postoperativemanagement were discussed. We suggest that the stage- Ⅲ a patients should be given surgical treatment,whereas, for the patients of stage- Ⅲ b, palliative operation was given just for the purpose of reliving thesymptoms.展开更多
Lung cancer is the leading cause of cancer-related mortality around the world. Despite advancements in diagnosis, surgical techniques, and neoadjuvant chemoradiotherapy over the last decade, the mortality rate is stil...Lung cancer is the leading cause of cancer-related mortality around the world. Despite advancements in diagnosis, surgical techniques, and neoadjuvant chemoradiotherapy over the last decade, the mortality rate is still high and the 5-year survival is a dismal 15%. Fortunately, early detection by low-dose computed tomography （LDCT） scans has reduced mortality by 20%; yet, overall, 5-year-survival remains low at less than 20%. Therefore, in order to ame- liorate this situation, a thorough understanding of the underlying molecular mechanisms is urgently needed. Chemo- kines and their receptors, crucial microenvironmental factors, play important roles in lung tumor genesis, progression, and metastasis, and exploring the mechanisms of this might bring new insights into early diagnosis and precisely targeted treatment. Consequently, this review will mainly focus on recent advancements on the axes of chemokines and their receptors of lung cancer.展开更多
文摘目的目前临床治疗中利用调强放射治疗(IMRT)联合化疗治疗非小细胞癌(NSCLC)的研究较少。文中旨在分析化疗联合IMRT治疗局部进展期NSCLC患者的疗效及对生存质量的影响。方法选择2012年1月至2014年12月苏州大学附属第一医院放疗科收治的160例局部进展期NSCLC患者,根据治疗方式不同分为IMRT组(紫杉醇或吉西他滨联合顺铂化疗,调强放射治疗)和对照组(仅紫杉醇或吉西他滨联合顺铂化疗),每组80例。比较2组患者治疗效果及对患者生存质量的影响。结果 IMRT组治疗有效率高于对照组(78.75%vs 47.50%,P<0.05)。IMRT组患者1年、2年、3年生存率(70.00%、52.50%、36.25%)明显高于对照组(52.50%、36.25%、21.25%),差异有统计学意义(P<0.05)。IMRT组患者中位疾病进展时间、中位生存期明显大于对照组[8.9 vs 6.3个月,14.2 vs 11.1个月],差异均有统计学意义(P<0.05)。IMRT组不良反应发生率与对照组比较差异无统计学意义(P>0.05)。结论局部进展期NSCLC者采用化疗联合IMRT能显著提高治疗效果,不良反应较少,安全性高,明显延长患者生存期,值得临床推广使用。
文摘Objective： To study the clinical efficacy and methods of permanent implantation of radioactive I-125 seed in surgery for local advanced non small lung cancer （LANSCLC）. Methods： From Apr. 2004 to Apr. 2006, the I-125 seeds were implanted into 30 patients with LANSCLC in surgery. The numbers of seeds were 10-40. The chemotherapy was performed in 10 to 14 days after operation. Results： There was no operative death, and the distribution of seeds and complications were reviewed by CT and X-ray after treatment. The distribution of seeds was satisfactory in all patients. The complete response rate （CR） was 56.6% and the part response （PR） was 26.6%. The overall response rate was 83.3% after 4-24 months of surgery. There was no one occurred radiation pneumonia. Prospective efficacy await further follow-up. Conclusion： Permanent implantation of 1-125 seed in surgery for LANSCLC, is a safe and effective method with mild complications.
文摘During a 12-year period, 44 patients were surgically treated for stage- Ⅲ peripheral squamous cell car-cinoma of the right upper lobe. The mean time from the discovery of the shadow in the right upper lobe tothe confirmation of the diagnosis was 2 months. All patients underwent the resection of the right upperlobe with the dissection of the right mediastinal lymph nodes, among them, 4 patients had sleeve lobectomy of the right upper lobe. P-TNM staging: 23 cases were in stage- Ⅲ a, 21 cases in stage- Ⅲ b. The fre-quency of the postoperative complications was 20- 4 % (9/44 cases). The 1-year survival rate of all patientswas 61 % (27/44 cases). None of stage - Ⅲ b patients lived longer than 3 years. The postoperative 3-and 5-year survival rates of stage- Ⅲ a cases were 65. 2 % (15/23cases) and 21. 7 % (5/23 cases) respectively. Inthis article, the patients clinical features, the causes of delayed-diagnosis, the operative and postoperativemanagement were discussed. We suggest that the stage- Ⅲ a patients should be given surgical treatment,whereas, for the patients of stage- Ⅲ b, palliative operation was given just for the purpose of reliving thesymptoms.
基金Project supported by the Science and Technology Commission of Shanghai Municipality(No.14140901400)the Natural Science Foundation of Shanghai(No.13ZR1435000)the National Natural Science Foundation of China(No.81372318)
文摘Lung cancer is the leading cause of cancer-related mortality around the world. Despite advancements in diagnosis, surgical techniques, and neoadjuvant chemoradiotherapy over the last decade, the mortality rate is still high and the 5-year survival is a dismal 15%. Fortunately, early detection by low-dose computed tomography （LDCT） scans has reduced mortality by 20%; yet, overall, 5-year-survival remains low at less than 20%. Therefore, in order to ame- liorate this situation, a thorough understanding of the underlying molecular mechanisms is urgently needed. Chemo- kines and their receptors, crucial microenvironmental factors, play important roles in lung tumor genesis, progression, and metastasis, and exploring the mechanisms of this might bring new insights into early diagnosis and precisely targeted treatment. Consequently, this review will mainly focus on recent advancements on the axes of chemokines and their receptors of lung cancer.
